A Mathematical Model of COVID-19 Transmission

Autor: Jayatilaka R, Patel R, Brar M, Tang Y, Nm, Jisrawi, Farrukh Chishtie, Drozd J, Sr, Valluri

Publikováno v: Europe PubMed Central
Materials Today. Proceedings
Physics and Astronomy Publications

Disease transmission is studied through disciplines like epidemiology, applied mathematics, and statistics. Mathematical simulation models for transmission have implications in solving public and personal health challenges. The SIR model uses a compa

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bce0fa15489259c9716ce9d49c210176

Real-world effectiveness of original BNT162b2 mRNA COVID-19 against symptomatic Omicron infection among children 5-11 years of age in Brazil: A prospective test-negative design study.

Autor: Rodrigues CO; Faculty of Medicine, Campus Toledo, Federal University of Paraná (UFPR), Brazil., Spinardi J; Pfizer, Vaccines Medical and Scientific Affairs, Emerging Markets, Collegeville, PA, USA., Rosa RG; Internal Medicine Department, Hospital Moinhos de Vento (HMV), Porto Alegre, RS, Brazil; Research Unit, Inova Medical, Porto Alegre, RS, Brazil; Research Institute, HMV, Porto Alegre, RS, Brazil. Electronic address: regisgoulartrosa@gmail.com., Falavigna M; Research Unit, Inova Medical, Porto Alegre, RS, Brazil; Research Institute, HMV, Porto Alegre, RS, Brazil; Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada., de Souza EM; Department of Biochemistry and Molecular Biology, Department of Genetics, UFPR, Brazil., Manfio JL; Research Institute, HMV, Porto Alegre, RS, Brazil., de Souza AP; Research Institute, HMV, Porto Alegre, RS, Brazil., de Araujo CLP; Research Institute, HMV, Porto Alegre, RS, Brazil., Cohen M; Research Institute, HMV, Porto Alegre, RS, Brazil; Federal University of Rio Grande do Sul (UFRGS), Brazil., Barbosa GRGDV; Research Institute, HMV, Porto Alegre, RS, Brazil., Silva FKR; Research Institute, HMV, Porto Alegre, RS, Brazil., Sganzerla D; Research Institute, HMV, Porto Alegre, RS, Brazil., da Silva MMD; Research Institute, HMV, Porto Alegre, RS, Brazil., Ferreira D; Otus Solutions, Porto Alegre, RS, Brazil., Kunkel NT; Research Institute, HMV, Porto Alegre, RS, Brazil., Camargo NI; Research Institute, HMV, Porto Alegre, RS, Brazil., Sarturi JC; Research Institute, HMV, Porto Alegre, RS, Brazil., Guilhem MC; Research Institute, HMV, Porto Alegre, RS, Brazil., de Oliveira JC; Department of Biochemistry and Molecular Biology, Department of Genetics, UFPR, Brazil., Lopes CC; Research Institute, HMV, Porto Alegre, RS, Brazil., Widmar F; Research Institute, HMV, Porto Alegre, RS, Brazil., Barufi LK; Research Institute, HMV, Porto Alegre, RS, Brazil., da Silva GN; Research Institute, HMV, Porto Alegre, RS, Brazil., Gradia DF; Department of Biochemistry and Molecular Biology, Department of Genetics, UFPR, Brazil., Brandalize APC; Faculty of Medicine, Campus Toledo, Federal University of Paraná (UFPR), Brazil., Royer CA; Department of Biochemistry and Molecular Biology, Department of Genetics, UFPR, Brazil., Luiz RM; Faculty of Medicine, Campus Toledo, Federal University of Paraná (UFPR), Brazil., Baura VA; Department of Biochemistry and Molecular Biology, Department of Genetics, UFPR, Brazil., Abreu H; Department of Biochemistry and Molecular Biology, Department of Genetics, UFPR, Brazil., Poitevin CG; Department of Biochemistry and Molecular Biology, Department of Genetics, UFPR, Brazil., Kucharski GA; Department of Health of Toledo, Toledo, PR, Brazil., Pedrotti F; Department of Health of Toledo, Toledo, PR, Brazil., Valluri SR; Pfizer, Vaccines Medical and Scientific Affairs, Emerging Markets, Collegeville, PA, USA., Srivastava A; Pfizer, Vaccines Medical and Scientific Affairs, Emerging Markets, Collegeville, PA, USA; Orbital Therapeutics, Cambridge MA, USA., Julião VW; Pfizer, Vaccines Medical and Scientific Affairs, Emerging Markets, Collegeville, PA, USA., Melone OC; Pfizer, Vaccines Medical and Scientific Affairs, Emerging Markets, Collegeville, PA, USA., Allen KE; Pfizer, Vaccines Medical and Scientific Affairs, Emerging Markets, Collegeville, PA, USA., Kyaw MH; Pfizer, Vaccines Medical and Scientific Affairs, Emerging Markets, Collegeville, PA, USA., Castillo GDCM; Pfizer, Vaccines Medical and Scientific Affairs, Emerging Markets, Collegeville, PA, USA., McLaughlin JM; Pfizer, Vaccines Medical and Scientific Affairs, Emerging Markets, Collegeville, PA, USA.

Publikováno v: Immunology letters [Immunol Lett] 2024 Oct; Vol. 269, pp. 106903. Date of Electronic Publication: 2024 Jul 26.

Effectiveness of BNT162b2 Vaccine for Preventing COVID-19-Related Hospitalizations: A Test-Negative Case-Control Study.

Autor: Keane A; Department of Pediatrics, Emory University School of Medicine, Atlanta, GA 30322, USA., Tippett A; Department of Pediatrics, Emory University School of Medicine, Atlanta, GA 30322, USA., Taylor EG; Department of Pediatrics, Emory University School of Medicine, Atlanta, GA 30322, USA., Reese O; Department of Pediatrics, Emory University School of Medicine, Atlanta, GA 30322, USA., Salazar L; Department of Pediatrics, Emory University School of Medicine, Atlanta, GA 30322, USA., De Castro K; Department of Pediatrics, Emory University School of Medicine, Atlanta, GA 30322, USA., Choi C; Department of Pediatrics, Emory University School of Medicine, Atlanta, GA 30322, USA., Ciric C; Department of Pediatrics, Emory University School of Medicine, Atlanta, GA 30322, USA., Taylor M; Department of Pediatrics, Emory University School of Medicine, Atlanta, GA 30322, USA., Mitchell A; Department of Pediatrics, Emory University School of Medicine, Atlanta, GA 30322, USA., Gibson T; Department of Pediatrics, Emory University School of Medicine, Atlanta, GA 30322, USA., Puzniak L; Pfizer, Inc., New York, NY 10017, USA., Hubler R; Pfizer, Inc., New York, NY 10017, USA., Valluri SR; Pfizer, Inc., New York, NY 10017, USA., Wiemken TL; Pfizer, Inc., New York, NY 10017, USA., Lopman BA; Rollins School of Public Health, Emory University, Atlanta, GA 30322, USA., Kamidani S; Department of Pediatrics, Emory University School of Medicine, Atlanta, GA 30322, USA.; Center for Childhood Infections and Vaccines, Children's Healthcare of Atlanta, Atlanta, GA 30322, USA., Anderson LJ; Department of Pediatrics, Emory University School of Medicine, Atlanta, GA 30322, USA.; Center for Childhood Infections and Vaccines, Children's Healthcare of Atlanta, Atlanta, GA 30322, USA., McLaughlin JM; Pfizer, Inc., New York, NY 10017, USA., Rostad CA; Department of Pediatrics, Emory University School of Medicine, Atlanta, GA 30322, USA.; Center for Childhood Infections and Vaccines, Children's Healthcare of Atlanta, Atlanta, GA 30322, USA., Anderson EJ; Department of Pediatrics, Emory University School of Medicine, Atlanta, GA 30322, USA.; Center for Childhood Infections and Vaccines, Children's Healthcare of Atlanta, Atlanta, GA 30322, USA.; Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, GA 30322, USA.

Publikováno v: Vaccines [Vaccines (Basel)] 2024 Jun 13; Vol. 12 (6). Date of Electronic Publication: 2024 Jun 13.

Effectiveness of BNT162b2 BA.4/5 bivalent mRNA vaccine against a range of COVID-19 outcomes in a large health system in the USA: a test-negative case-control study.

Autor: Tartof SY; Department of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USA; Department of Health Systems Science, Kaiser Permanente Bernard J Tyson School of Medicine, Pasadena, CA USA. Electronic address: sara.y.tartof@kp.org., Slezak JM; Department of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USA., Puzniak L; Pfizer, Collegeville, PA, USA., Hong V; Department of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USA., Frankland TB; Kaiser Permanente Hawaii Center for Integrated Health Care Research, Honolulu, HI, Hawaii., Ackerson BK; Southern California Permanente Medical Group, Harbor City, CA, USA., Xie F; Department of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USA., Takhar H; Department of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USA., Ogun OA; Department of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USA., Simmons S; Department of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USA., Zamparo JM; Pfizer, Collegeville, PA, USA., Valluri SR; Pfizer, Collegeville, PA, USA., Jodar L; Pfizer, Collegeville, PA, USA., McLaughlin JM; Pfizer, Collegeville, PA, USA.

Publikováno v: The Lancet. Respiratory medicine [Lancet Respir Med] 2023 Dec; Vol. 11 (12), pp. 1089-1100. Date of Electronic Publication: 2023 Oct 25.

An open-label extension of a phase 2 dose-finding study of once-weekly somatrogon vs. once-daily Genotropin in children with short stature due to growth hormone deficiency: results following 5 years of treatment.

Autor: Zadik Z; Pediatric Endocrinology, Kaplan Medical Center, Rehovot, Israel., Zelinska N; Ukrainian Scientific and Practical Center of Endocrine Surgery, Transplantation Endocrine Organs and Tissues of the Ministry of Health of Ukraine, Kyiv, Ukraine., Iotova V; Department of Pediatrics, Medical University of Varna, UMHAT 'Sv. Marina', Varna, Bulgaria., Skorodok Y; Saint-Petersburg State Pediatric Medical University, Saint-Petersburg, Russia., Malievsky O; Bashkirian State Medical University, Ufa, Russia., Mauras N; Nemours Children's Health, Jacksonville, FL, USA., Valluri SR; Pfizer Inc, New York, NY, USA., Pastrak A; OPKO Health, Toronto, ON, Canada., Rosenfeld R; Oregon Health and Science University, Portland, OR, USA.

Publikováno v: Journal of pediatric endocrinology & metabolism : JPEM [J Pediatr Endocrinol Metab] 2023 Feb 03; Vol. 36 (3), pp. 261-269. Date of Electronic Publication: 2023 Feb 03 (Print Publication: 2023).